|View printer-friendly version|
|September 23, 2003 4:44 p.m.|
|Teva and Acorda Therapeutics Agree to Co-Develop and Co-Promote Valrocemide in The U.S.|
Teva Receives Right Of First Negotiation For Acorda's Fampridine-SR
Jerusalem, Israel, and Hawthorne, NY, September 23, 2003, September 23, 2003 - Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) and Acorda Therapeutics, Inc. announced today that they have entered into a strategic collaboration to co-develop and co-promote valrocemide for several indications. The parties plan to initially develop the product for the treatment of epilepsy.